Policy & Regulation
Omeros Finalises with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
18 January 2019 - - US-based commercial-stage biopharmaceutical company Omeros Corp. (NASDAQ: OMER) has finalised its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy f...
Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
18 January 2019 - - US-based biopharmaceutical company Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) has completed patient dosing in the company's TIME-2b study, a Phase 2b clinical trial designed ...
vTv Therapeutics Publishes Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
18 January 2019 - - A new paper in Science Translational Medicine showcases the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase act...
Amedex to commence Phase 2 cDFU clinical trial of Nu-3 antimicrobial in patients with chronic diabetic foot ulcers in The Bahamas
18 January 2019 - Pharmaceuticals company Amedex Inc said on Thursday that it plans to conduct two Phase 2 cDFU clinical trial for its topically applied Nu-3 antimicrobial used to eliminate infection ...
Janssen Pharmaceutical's Erleada receives European Commission marketing approval
18 January 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson has received marketing approval from the European Commission (EC) for Erleada (apalutamide) intended to treat non-metast...
Revance Eyes USD 100m from Common Stock Offering
17 January 2019 - - US-based biotechnology company Revance Therapeutics, Inc. (NASDAQ: RVNC) has proposed underwritten public offering in which it will issue and sell approximately USD 100m of shares ...